Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T40276 | Target Info | |||
| Target Name | Protein kinase C beta (PRKCB) | ||||
| Synonyms |
Protein kinase C beta type; PRKCB1; PKCB; PKC-beta; PKC-B
Click to Show/Hide
|
||||
| Target Type | Clinical trial Target | ||||
| Gene Name | PRKCB | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Protein kinase C alpha (PRKCA) | Successful Target | ||||
| UniProt ID | KPCA_HUMAN | |||||
| Gene Name | PRKCA | |||||
| Synonyms |
Protein kinase C alpha type; PRKACA; PKCalpha; PKCA; PKC-alpha; PKC-A
Click to Show/Hide
|
|||||
| Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 39 nM | Click to Show More | [1] | |
| 2 | LY333531 | Drug Info | IC50 = 360 nM | [2] | ||
| 3 | LY333531 | Drug Info | IC50 = 360 nM | [3] | ||
| Co-Target Name | Protein kinase C gamma (PRKCG) | Successful Target | ||||
| UniProt ID | KPCG_HUMAN | |||||
| Gene Name | PRKCG | |||||
| Synonyms |
PRKCG; PKCG; PKC-gamma
Click to Show/Hide
|
|||||
| Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 83 nM | Click to Show More | [1] | |
| 2 | LY333531 | Drug Info | IC50 = 300 nM | [2] | ||
| 3 | LY333531 | Drug Info | IC50 = 300 nM | [1] | ||
| Co-Target Name | Protein kinase C epsilon (PRKCE) | Successful Target | ||||
| UniProt ID | KPCE_HUMAN | |||||
| Gene Name | PRKCE | |||||
| Synonyms |
Protein kinase C epsilon type; PKCE; PKC epsilon; NPKC-epsilon
Click to Show/Hide
|
|||||
| Representative Drug(s) | Enzastaurin | Drug Info | IC50 = 110 nM | Click to Show More | [1] | |
| 2 | LY333531 | Drug Info | IC50 = 600 nM | [4] | ||
| 3 | LY333531 | Drug Info | IC50 = 600 nM | [2] | ||
| Co-Target Name | Serine/threonine-protein kinase pim-1 (PIM1) | Clinical trial Target | ||||
| UniProt ID | PIM1_HUMAN | |||||
| Gene Name | PIM1 | |||||
| Synonyms |
Pim-1 proto-oncogene, serine/threonine kinase; PIM
Click to Show/Hide
|
|||||
| Representative Drug(s) | LY333531 | Drug Info | IC50 = 200 nM | [5] | ||
| Co-Target Name | Protein kinase C delta (PRKCD) | Clinical trial Target | ||||
| UniProt ID | KPCD_HUMAN | |||||
| Gene Name | PRKCD | |||||
| Synonyms |
nPKC-delta; Tyrosine-protein kinase PRKCD; SDK1; Protein kinase C delta type catalytic subunit; Protein kinase C delta type; PKC-delta
Click to Show/Hide
|
|||||
| Representative Drug(s) | LY333531 | Drug Info | IC50 = 250 nM | Click to Show More | [4] | |
| 2 | LY333531 | Drug Info | IC50 = 250 nM | [2] | ||
| 3 | Enzastaurin | Drug Info | IC50 = 1000 nM | [2] | ||
| Co-Target Name | Phosphoinositide dependent protein kinase-1 (PDPK1) | Clinical trial Target | ||||
| UniProt ID | PDPK1_HUMAN | |||||
| Gene Name | PDPK1 | |||||
| Synonyms |
PDK1; HPDK1; 3-phosphoinositide-dependent protein kinase 1; 3-Phosphoinositide-dependent kinase-1; 3'-phosphoinositide dependent kinase 1
Click to Show/Hide
|
|||||
| Representative Drug(s) | LY333531 | Drug Info | IC50 = 750 nM | [1] | ||
| Co-Target Name | Protein kinase C eta (PRKCH) | Co-Target | ||||
| UniProt ID | KPCL_HUMAN | |||||
| Gene Name | PRKCH | |||||
| Synonyms |
Protein kinase C eta type; PKC-L; nPKC-eta
Click to Show/Hide
|
|||||
| Representative Drug(s) | LY333531 | Drug Info | IC50 = 52 nM | Click to Show More | [4] | |
| 2 | LY333531 | Drug Info | IC50 = 52 nM | [2] | ||
| 3 | Enzastaurin | Drug Info | IC50 = 400 nM | [2] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition. Bioorg Med Chem. 2018 Aug 7;26(14):4209-24. | ||||
| REF 2 | Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett. 2003 Jun 2;13(11):1857-9. | ||||
| REF 3 | Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors. J Med Chem. 2003 Sep 11;46(19):4021-31. | ||||
| REF 4 | (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. | ||||
| REF 5 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.